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Abstract
Background: The tumor microenvironment is pivotal in tumor progression. Thus, we aimed to develop a
mammary tumor model to elucidate molecular characteristics in the stroma versus the tumor cell compartment by
global gene expression. Secondly, since tumor hypoxia influences several aspects of tumor pathophysiology, we
hypothesized that hyperoxia might have an inhibitory effect on tumor growth per se. Finally, we aimed to identify
differences in gene expression and key molecular mechanisms, both in the native state and following treatment.
Methods: 4T1 dsRed breast cancer cells were injected into eGFP expressing NOD/SCID mice. Group 1 was exposed
to 3 intermittent HBO treatments (Day 1, 4 and 7), Group 2 to 7 daily HBO treatments (both 2.5bar, 100% O2, à 90
min), whereas the controls were exposed to a normal atmosphere. Tumor growth, histology, vascularisation, cell
proliferation, cell death and metastasis were assessed. Fluorescence-activated cell sorting was used to separate
tumor cells from stromal cells prior to gene expression analysis.
Results: The purity of sorted cells was verified by fluorescence microscopy. Gene expression profiling
demonstrated that highly expressed genes in the untreated tumor stroma included constituents of the extracellular
matrix and matrix metalloproteinases. Tumor growth was significantly inhibited by HBO, and the MAPK pathway
was found to be significantly reduced. Immunohistochemistry indicated a significantly reduced microvessel density
after intermittent HBO, whereas daily HBO did not show a similar effect. The anti-angiogenic response was
reflected in the expression trends of angiogenic factors.
Conclusions: The present in vivo mammary tumor model enabled us to separate tumor and stromal cells, and
demonstrated that the two compartments are characterized by distinct gene expressions, both in the native state
and following HBO treatments. Furthermore, hyperoxia induced a significant tumor growth-inhibitory effect, with
significant down-regulation of the MAPK pathway. An anti-angiogenic effect after intermittent HBO was observed,
and reflected in the gene expression profile.
Background
The tumor microenvironment is increasingly recognized
as a pivotal factor in tumor progression [1], and studies
show that the tumor stroma strongly influences angio-
genesis and vascular permeability [2-4]. Understanding
the biological heterogeneity in primary cancers and their
metastases, and the process by which tumor cells invade
distant tissues, is necessary to develop effective cancer
therapies [5]. The non-obese diabetic/severe combined
immunodeficient (NOD/SCID) mice expressing
enhanced-green fluorescent protein (eGFP), combined
with dsRed transfected tumor cells enables studies of
tumor-stroma cell interactions, both in situ and ex vivo
[6]. Fluorescence-activated cell sorting (FACS) enables
complete separation of green stromal cells from red
tumor cells and provides a system for detailed analysis
of tumor-stroma interactions.
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Hypoxia activates signalling pathways that regulate
cellular proliferation, angiogenesis and cell death [7].
Adaptation to these pathways allows cancer cells to sur-
vive and even grow under hypoxic conditions. The fact
that tumors contain hypoxic areas was discovered nearly
sixty years ago and was shown to correlate with poor
response to radiotherapy [8,9]. Later, hypoxia has also
been shown to decrease the efficacy of chemotherapy
and has been associated with a poor treatment outcome
[10,11].
Due to the tumor-promoting effects of hypoxia, a
reduction in the hypoxic state of the tumor might have
an inhibitory effect on tumor growth. Previously, induc-
tion of hyperoxia by hyperbaric oxygen (HBO), have
demonstrated successful growth inhibition and potentia-
tion of the chemotherapeutic effect [12-16]. HBO is
based on 100% oxygen exposure at a pressure level
higher than normal atmospheric pressure, thereby
enhancing the amount of dissolved oxygen in the
plasma [17].
We aimed to establish a model system for studying
tumor-stroma interactions in 4T1 mammary tumors.
This model enables separation of eGFP labelled stromal
cells from dsRed transfected 4T1 mammary tumor cells,
and provides an opportunity to elucidate changes in
gene expression in the two compartments. Furthermore,
using this model we aimed to study the biological effects
of enhanced oxygenation on tumor growth and
regression.
Methods
Cell line and culture conditions
The murine mammary cell line 4T1 (American Type
Culture Collection, Rockville, MD, USA) was transfected
with red fluorescent protein using a dsRed-expressing
lentiviral vector. This cell line was originally isolated
from a spontaneously arising mammary tumor in BALB/
cfC3H mice [18]. Successful transfection with dsRed was
confirmed by fluorescence microscopy (Axiolmager 2,
Carl Zeiss MicroImaging, GmbH, Jena, Germany). 4T1
cells were cultured in RPMI-1640 medium (Bio-Whit-
taker, Verviers, Belgium) supplemented with 10% Foetal
Calf Serum (Sigma-Aldrich, Steinheim, Germany), 100
units/ml penicillin, 100 μg/ml streptomycin, 2% L-gluta-
mine (All from Bio-Whittaker, Verviers, Belgium). The
cells were maintained at 37°C in 5% CO2 and 95% air,
and were seeded and used at ~ 80% confluence in all
experiments.
Ethics Statement
All the animal experiments were performed in accor-
dance with the regulations of the Norwegian State Com-
mittee for Animal Research ("Forsøkdyrutvalget”,
approval number 1279) and approved by the Local
Institution Board at the University of Bergen (approval
number 2008076BB). The investigation conforms to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health.
In vivo experiments
Female NOD/SCID mice (18-24 g) were used in this
study. Generally, the NOD/SCID mice used expressed
eGFP in all nucleated cells, the exception being histolo-
gical and immunohistochemical experiments, where
plain NOD/SCID mice were used. The emission of
green fluorescence has previously been observed in mus-
cle, pancreas, kidney, heart and other organs of the
mice, confirming the fluorescent phenotype [6]. The
breeding was performed at the animal facility at the
University of Bergen, as described by Niclou et al. [6].
All animal experiments were performed under Isoflur-
ane (Rhone-Puolenc Chemicals, France) and N2O gas-
anaesthesia. A 17b-estradiol pellet (0.18 mg/pellet–60
day release, Innovative Research of America, Sarasota,
FL, USA) was inserted into the interscapular area of all
mice prior to tumor cell injection. The pellets provide a
continuous release of estradiol to give serum concentra-
tions of 150-250 pM. 3 × 106 4T1 cells dissolved in 0.15
ml PBS were injected in the mouse mammary fat pad,
in the groin area. 4T1 tumors had a 100% take rate, and
a 6 days latency period to a palpable tumor estimated to
be ~5 mm in diameter.
The tumors were measured externally with a calliper
at day 1 (pre HBO exposure), day 4 and 8 (post HBO
exposure). The location of the tumor excluded external
measurement in more than two dimensions. The tumor
volume was therefore calculated assuming a cylindrical
shape of the tumor, according to the formula: π/6 ·a2·b,
where a is the shortest and b is the longest transversal
diameter.
HBO treatment
A 27 l Hyperbaric Animal Research Chamber (OXY-
COM 250 ARC, HYPCOMOY, Tampere, Finland) with
an inner diameter of 25 cm, and an inner length of 55
cm was used. The chamber was supplied with pure O2.
After reaching 100% O2 (15 min), the pressure was
raised over a period of approximately 5 min to 2.5 bar
(equivalent to 15 meters sea water). The 2.5 bar pure
oxygen atmosphere was maintained for a period of 90
min. To maintain > 97% O2 atmosphere, the chamber
was flushed with pure oxygen for 3-5 min every 10-30
min depending on the number of mice in the chamber.
After treatment, the mice were slowly decompressed
over a 10 min period.
Three separate groups of mice were studied. The first
group of tumor bearing mice was exposed to intermit-
tent HBO treatment (2.5 bar and 100% O2, 3 exposures
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à 90 min on day 1, 4 and 7). The second group was
exposed to daily HBO treatments (2.5 bar and 100% O2,
7 daily exposures à 90 min), whereas the control group
was housed under normal atmosphere for the experi-
mental period of 8 days.
In situ and ex vivo imaging
We used a fluorescence dissection microscope (Model
C-DSD230, Nikon, Japan) with UV-filter optics for
dsRed and eGFP, to observe the tumor in situ. After the
mice were sacrificed with saturated KCl during anaes-
thesia, the tumors were excised. The tumors were pro-
cessed in three different ways: 1) formalin (4%), and
later embedded in paraffin. 2) frozen in liquid nitrogen
and stored at -80°C until further use. 3) paraformalde-
hyde (PFA) prior to freezing, and then embedded in
Prolong Gold (Invitrogen, CA, USA) after sectioning.
PFA fix was performed to conserve the fluorescent
traits, when visualized under the microscope (Leica TCS
SP5, Wetzlar, Germany).
Histology and immunohistochemistry
Paraffin embedded tumor sections from all three groups
were H&E stained, and examined by an experienced
pathologist.
Frozen tumor sections (20 μm) were used for immu-
nostaining of blood vessels using rat anti-mouse CD31
(AbD Serotec, Morphosys UK Ltd, Oxford, UK) as pri-
mary antibody and biotinylated rabbit anti-rat as sec-
ondary antibody (Vectastatin ABC kit, peroxidase IgG
PK 4004, Bioteam AS, Trondheim, Norway). An ABC
kit (Vectastatin ABC kit, peroxidase IgG PK 4004, Bio-
team AS, Trondheim, Norway) and Diaminobenzidine
tetrahydrochloride (3.3 DAB, Sigma Aldrich, Germany)
were used as a chromogen to visualize blood vessels.
Richardson stain was used as a nuclear counterstain.
The cross-sectional density of CD31 positive structures
was quantified per mm2 using a counter grid, covering
the viable tumor area. Tumor cell proliferation was
assessed by staining with an anti-rabbit Ki67 antibody
diluted 1:100 (Millipore, Billerica, MA), and biotinylated
goat anti-rabbit secondary antibody (DACO Patts,
Glostrup, Denmark) on frozen tumor sections. Four
Ki67 labelled “hot spots” within selected high power
fields of view (HPFs) were quantified using the NIS-Ele-
ments™ BR 3.1 software (Nikon Corporation, Tokyo,
Japan), under 400× magnification. The immunopositive
cells were counted and expressed as a fraction (%) of
the total cells. Four fields of vision per section from
each animal were included in the quantification. Cell
death was examined by the terminal transferase-
mediated dUTP nick-end-labeling (TUNEL) method
(Boehringer Mannheim, Mannheim, Germany), per-
formed according to the manufacturers recommendation
on frozen tumor sections. For quantifying TUNEL
labelled cells, threshold levels of pixel intensity were
determined and expressed as % positive cells/area frac-
tion at x200 magnification. All sections were examined
using a Nikon light microscope (THP Eclipse E600,
Nikon Corporation) and the images were captured with
a Nikon Digital Camera (DXM 1,200F, Nikon Corpora-
tion). The quantification was performed blindly.
Fluorescence-activated cell sorting (FACS)
Freshly isolated 4T1 tumors were dissociated by mincing
the tissue with scalpels, followed by incubation with 1
mg/ml collagenase/dispatase (Roche Diagnostics GmbH,
Germany) and 0.125% DNase I (Sigma-Aldrich) dis-
solved in DMEM medium for 60-90 min at 37°C.
Incompletely dissociated tissue was digested a second
time using the same procedure. The dissociated tumor
tissue was then washed with ice-cold FACS buffer (PBS
with 2% FBS) and filtered twice through a 70-μm cell
strainer. The cell suspension was then centrifuged at a
speed of 500 G for 10 min (4°C). The cell pellets were
resuspended in FACS buffer for further analysis and
sorting. The single cell suspension was filtered through
a 40-μm cell strainer in order to remove any clumping
cells before sorting. The cells were sorted using a cell
sorter (FACS Aria SORP, BD Biosciences, Erembode-
gem, Belgium) based on the single-cell viability and the
fluorescence intensity of eGFP and dsRed, and separa-
tion was confirmed by fluorescence microscopy (Nikon
ellipse 2000, Nikon, Japan).
RNA isolation and quantification
Sorted cells were lysed using 350 μl Buffer RLT Plus
with b-mercaptoethanol (b-ME). The lysate was homo-
genized by passing it 5 times through a 23 G needle.
Further, the protocol for purification of total RNA from
animal cells (RNeasy Plus Mini Handbook, Qiagen AB,
Sweden) was used according to the manufacturer’s
recommendations. RNA concentration (ng/μl) and pur-
ity (260/280 ratio) were determined using NanoDrop
1,000 Spectrophotometer (Thermo Scientific, Sweden).
Gene expression analysis
Global gene expression analysis was performed in order
to identify key molecular mechanisms and differences in
gene programs in stromal and tumor cells, as well as
changes following HBO treatment. A total of 18 tumor
bearing mice were used. Seven mice served as control
animals (non-HBO exposure), 5 mice were HBO treated
intermittently and 6 mice treated daily. Stromal cells
and tumor cells from the different tumors were isolated
as described above. Total RNA purification, cRNA label-
ing, microarray hybridization and features extraction
were performed as previously described [14]. The
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Agilent G4122F Whole Mouse Genome (4 × 44 k) Oligo
Microarray Kit with SurePrint Technology (Agilent
Technologies, Inc., Palo Alto, CA) was used to analyze
samples in the present study. The normalized channel
values were log (2) transformed and combined into a
gene expression data matrix. Data were formatted in a
J-Express-file suitable for additional data mining (http://
www.molmine.com/) [19]. Following normalization, the
treated tumor cells and stromal cells were analysed
against the respective non-treated controls of stromal
and tumor cells. We also analysed untreated stromal
cells against untreated tumor cells to highlight and char-
acterize the stromal cell signatures. A similar approach
was performed to analyse how the treated tumor cells
responded to HBO treatment versus treated stromal
cells (results not shown).
Statistical analysis
For the gene expression data, we used analysis of var-
iance (ANOVA), SAM (Significant Analysis of Microar-
ray), GSEA (Gene Sets Enrichment Analysis) [20] and
Gaussian kernels of the J-Express program package for
identification of differentially expressed genes. Following
SAM we selected genes with False Discovery Rate (FDR)
< 5% as basis for GSEA and Hierarchical clustering.
Gene sets consisting of more than 18 genes and less
than 200 genes were selected for further analysis of cel-
lular processes, pathways and molecular function. Anno-
tated microarray data were uploaded in the BASE
database and formatted and exported to ArrayExpress at
the European Bioinformatics Institute (http://www.ebi.
ac.uk/arrayexpress (Accession number: E-TABM-1103))
in agreement with the MIAME guidelines. Two-tailed
unpaired t-test (normalized data) or the non-parametric
Mann-Whitney test (non-normalized data) was used for
testing the statistical differences between groups. P <
0.05 was considered statistically significant. GraphPad
InStat 3 (GraphPad Software, Inc., La Jolla, USA) and
SPSS for Windows (IBM Corporation, NY, USA) were
used for the statistical analysis.
Results
Fluorescent imaging
To verify tumor growth in the eGFP mice (Figure 1A), a
fluorescence dissection microscope with UV-filter optics
for dsRed and eGFP was used. As shown in Figure 1B, a
red 4T1 mammary tumor was seen within the surround-
ing green host tissue. The overall tumor surface archi-
tecture was visualized, and blood vessels within the
tumor bed appeared darker. The vasculature in the skin
flap as well as the transition areas between tumor tissue
and host tissue was also clearly visualized. Thus, dsRed
transfected 4T1 mammary tumors were successfully
established subcutaneously (sc) in the eGFP mice.
Confocal microscopy revealed that the tumors contained
both red tumor cells as well as infiltrating eGFP expres-
sing stromal cells (Figure 1C and 1D). Before separating
the tumor cells from the stromal cells using FACS, the
tumor bulk was dissociated (Figure 1E). Further, a suc-
cessful separation of the green stromal cells from the
red tumor cells was confirmed by fluorescence micro-
scopy (Figure 1F).
Tumor growth
Both untreated and HBO treated 4T1 mammary tumors
were measured. Six days after injection of the 4T1 cells,
the average size of all tumors were approximately 80
mm3 (day 1). The control tumors (n = 19) increased in
size with ~800% within the first 8 days of tumor devel-
opment (Figure 2). Exposing the mice to 2.5 bar pure
Figure 1 dsRed transfected 4T1 mammary tumor in eGFP mice.
A) Two NOD/SCID mice expressing enhanced green fluorescent
protein (eGFP) under UV-illumination flanking one plain NOD/SCID
mouse from the non-transgenic parental line. B) An in situ picture of
a 4T1 dsRed tumor growing subcutaneously in the NOD/SCID eGFP
expressing mouse after removing the skin flap (×40 magnification).
C and D) Representative confocal microscopy pictures of a 4T1
mammary control tumor, with dsRed expressing tumor cells, as well
as infiltrating eGFP expressing host cells. Scale bars indicate 250 μm
(C) and 50 μm (D). E) The dissociated 4T1 mammary tumor showing
single eGFP expressing host cells together with single dsRed
transfected tumor cells (×100 magnification). F) eGFP expressing
stromal cells and dsRed expressing 4T1 tumor cells after
Fluorescence activated cell sorting (FACS), verify successful
separation.
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oxygen (n = 24), on days 1, 4 and 7, each for 90 min,
inhibited tumor growth significantly compared to
untreated control tumors during the same time period
(p < 0.001) (Figure 2). A similar reduction was found
after daily HBO exposure (n = 9) 7 times (p < 0.001).
Thus, enhanced oxygenation significantly inhibited the
growth of the 4T1 mammary tumors.
Tumor morphology
Control 4T1 tumors (n = 7) were highly cellular and
revealed an undifferentiated morphology showing both
epitheloid and spindle shaped tumor cells, marked
nuclear atypia and numerous mitotic figures, with dif-
fuse growth in the surrounding fat tissue. They also
showed minimal to extensive (~ 70-80%) necrosis with
areas of granulation tissue. In the tumors treated with
intermittent HBO (n = 5) and daily HBO (n = 9), no
clear differences from control tumors were evident.
Tumor blood vessels
Angiogenesis is pivotal for tumor growth, and may be a
strong contributor to the differences in tumor size
observed between controls and the HBO treated groups.
We therefore quantified the average number of CD31
positive tumor blood vessels (blood vessels/mm2). A
concomitant study from our group demonstrated that
intermittent HBO significantly decreased tumor blood
vessel density compared to controls (~50%), (Table 1)
[21]. However, we now demonstrate that the tumor
blood vessel density is not affected by 7 daily treatments
of HBO. Thus, only intermittent HBO (3 HBO expo-
sures) has a strong anti-angiogenic effect on the 4T1
mammary tumors.
Cell death and proliferation
The balance between cell proliferation and cell death is
an important factor deciding the tumor growth rate. We
therefore aimed to investigate the amount of cell death
by using TUNEL staining and proliferation by using
Ki67 staining. The results showed that there were no
significant differences between the three experimental
groups, neither in proliferation nor cell death, when
counted in hot spot areas (Table 1).
Gene expression analysis
The purity of sorted cells was verified by fluorescence
microscopy. Additionally, gene expression profiling
demonstrated clear separation based on the expression
of mesenchymal markers in the stromal cells (Table 2).
Additional file 1: Figure S1 displays the number of
genes significantly changed after treatment compared to
controls. 5,195 genes in the tumor cell compartment
were changed both following HBO daily and intermit-
tent treatment. In the stromal cell compartment, 4,802
genes were changed following both treatments. Addi-
tional file 2: Table S1, Additional file 3: Table S2, Addi-
tional file 4: Table S3, Additional file 5: Table S4
summarize the results from a Gene Set Enrichment
Analysis (GSEA), clustering the important signalling
pathways significantly changed in tumor cells and stro-
mal cells after intermittent and daily HBO treatment,
respectively. The expression of angiogenic markers in
both tumor and stromal cells after intermittent and
daily HBO were compared to untreated tumor and stro-
mal cells (Table 3), demonstrating that in this study,
enhanced oxygenation induced a down-regulation of
pro-angiogenic genes both in tumor and stromal cells in
Figure 2 Tumor growth. 4T1 mammary tumor growth (% of initial
volume) in control (n = 19), intermittent (n = 24) and daily (n = 9)
hyperbaric oxygen (HBO) treated tumors during an 8 day period.
Intermittent treatments were given at day 1, 4 and 7. Data
represent mean ± SEM. * p < 0.001 compared to control.
Table 1 Immunohistochemical analysis
Control Intermittent HBO Daily HBO
Angiogenesis (numbers/mm2) 79.9 ± 18.7Δ 41.8 ± 17.1*Δ 79.2 ± 16.2
Proliferation
(% Ki67-positive cells)
21.7 ± 17.6 26.5 ± 17.9 21.4 ± 7.8
Cell death
(% of total area)
7.6 ± 4.1 7.8 ± 1.3 5.8 ± 0.8
Angiogenesis (CD31), proliferation (Ki67) and cell death (TUNEL) stained in tumors from untreated controls and after intermittent and daily hyperbaric oxygen
treatment (HBO). n = 5 in all groups. Mean values ± SD. *p < 0.02 compared to both control and daily HBO treatment. Δresults obtained from Jevne et al. [21]
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the intermittent group. Moreover, in the daily HBO
treated group, expression of pro-angiogenic genes was
down-regulated in tumor cells, although fewer genes
were significantly changed. Figure 3 displays a heat map
of the VEGF-signalling pathway (HSA04370), showing
that this important pro-angiogenic pathway is down-
regulated in tumor cells after intermittent HBO, but not
significantly changed in tumor cells after daily HBO.
The MAPK pathway (HSA04010) was significantly
down-regulated in both tumor and stromal cells after
daily and intermittent HBO compared to untreated con-
trol (Figure 4a and 4b).
Discussion
Tumor and stroma in untreated control tumors
Proliferation, survival and migration of breast cancer
cells can be modulated by stromal cells [22]. Microar-
ray studies have made it possible to molecularly clas-
sify breast cancers, and correlate their signatures with
metastatic behaviour and clinical outcome [23]. Never-
theless, since most of the in vivo studies have been
performed on tumor tissue homogenates that provides
material based on all cell types it does not allow for
separate assessment of the tumor cells and stromal
compartments in solid tumors, and so, subtle changes
within one compartment may be masked by the bulk
of surrounding cells. Thus, by using red 4T1 cells
injected in green mice, we were able to investigate
complex tumor-stroma interactions, making a novel
contribution to the studies of tumor-host interactions
in mammary tumors.
Table 3 Markers of angiogenesis
Intermittent HBO Daily HBO
Tumor Stroma Tumor Stroma
Genes Gene name Fold
change
Fold
change
Fold
change
Fold change
Anti-Angiogenic
Serpinb5 Serine (or cysteine) peptidase inhibitor, clade B, member 5 3.4 1.6 5.0 NS
Csta Cystatin A 0.1 NS NS NS
Thbs1 Thrombospondin1 0.5 0.5 NS NS
Thbs2 Thrombospondin2 NS 2.7 NS 2.5
Thbs3 Thrombospondin3 NS NS 0.7 NS
Thbs4 Thrombospondin4 0.8 NS NS NS
Pro-angiogenic
HIF1a Hypoxia-inducible factor 1, alpha NS NS 0.7 NS
Pecam1 Platlet/endothelial cell adhesion molecule 1 0.9 0.5 0.6 NS
Vwf Von Willebrand factor homolog 0.7 0.3 NS 0.6
Vegfa Vascular endothelial growth factor A 0.5 0.5 NS 1.4
Vegfb Vascular endothelial growth factor B NS NS 0.7 NS
Vegfc Vascular endothelial growth factor C 0.6 NS 0.5 NS
Pdgfa Platelet derived growth factor, alpha 0.8 0.7 NS NS
Pdgfb Platelet derived growth factor, b 1.2 0.7 NS NS
Pdgfra Platelet derived growth factor receptor, alpha 0.7 2.3 0.5 2.1
Tgfb1 Transforming growth factor, beta 1 NS 0.8 0.8 NS
Il6 Interleukin 6 0.5 NS NS 0.3
Fgfr1 Fibroblast growth factor receptor 1 0.9 NS NS NS
Fgfr3 Fibroblast growth factor receptor 3 0.7 NS 0.7 NS
Egfr Epidermal growth factor receptor 0.5 NS 0.5 2.7
Serpinb2 Serine (or cysteine) peptidase inhibitor, clade B, member 2 0.6 NS NS 0.5
Displayed results are fold change of gene expression in intermittent and daily hyperbaric oxygen (HBO) treated tumors cells compared to untreated control
tumor cells, and intermittent and daily HBO treated stromal cells compared to untreated stromal cells. A positive fold change indicates increased expression after
treatment. FDR < 0.05%, NS = not significant
Table 2 Gene-signature of stromal cells
Epithelial markers in stroma
cells
Mesenchymal markers in stromal
cells
Krt14 0.3 Snai1 2
Cdh1 0.2 Snai2 19
Perp 0.3 Fgfr1 7
Dsp 0.1 Cdh2 2.3
Ocln 0.2 Cdh11 16
Cdh3 1.3 Twist2 25
Nid1 115
The numerals are referred to as fold change in gene expression of untreated
stromal cells as compared to untreated tumor cells. All values: FDR < 0.00%
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We have developed a mammary tumor model in
immunodeficient mice in order to separate the stromal
cells from the tumor cells, as indicated in Figure 1B.
Fluorescence microscopy (Figure 1F) showed a success-
ful separation of the green stromal cells from the red
tumor cells by FACS. Stromal cells expressed mesenchy-
mal markers, as indicated in Table 2, confirming their
origin. Gene expression results in the untreated control
tumors also verify expression-patterns of stromal cells,
with high expression of ECM genes, such as collagens
and integrins, in addition to high expression of MMP’s
and chemokines involved in invasion and metastasis
(data not shown).
Changes in tumor and stroma after enhanced
oxygenation
The present study aimed to elucidate the effect of
enhanced oxygenation on tumor growth and tumor-
stroma interactions. Previous studies from our labora-
tory have shown a significant tumor inhibitory effect of
intermittent HBO on DMBA (dimetyl-a-
benzantracene)-induced mammary tumors [12,14,16].
Thus, we wanted to expand our study of enhanced oxy-
genation to another mammary tumor model, to deter-
mine if HBO has a general inhibitory effect on breast
cancer. Both treatment regimens had a significant
growth-inhibitory effect on the present 4T1 tumor
model. However, the inhibitory effect was not as pro-
nounced in the present 4T1 tumors as for the DMBA-
induced tumors [12,14,16].
The number of genes significantly changed after treat-
ment compared to control is shown in Additional file 1:
Figure S1. To be able to systematize the gene expression
results, we have searched for important signalling path-
ways by GSEA. Signalling pathways significantly changed
in tumor cells and stromal cells after intermittent and
daily HBO treatment, respectively, is shown in Addi-
tional file 2: Table S1, Additional file 3: Table S2, Addi-
tional file 4: Table S3, Additional file 5: Table S4. The
results will be discussed further in the following
sections.
Angiogenesis
The importance of angiogenesis in tumor growth and
progression is well known, so a significant reduction in
tumor blood vessel density might be an important factor
explaining the tumor inhibitory effect after HBO. Immu-
nohistochemistry demonstrates a significant anti-angio-
genic effect after intermittent HBO treatment (Table 1).
This corresponds to the anti-angiogenic effect shown
previously on both DMBA-induced mammary tumors
and gliomas after intermittent HBO treatment [13,14].
Unexpectedly, immunohistochemistry did not show the
same anti-angiogenic effect after daily HBO. Table 3 dis-
plays important pro- and anti-angiogenic factors, and
show changes in gene expression in both tumor and
stromal cells treated with either intermittent or daily
HBO compared to untreated tumor or stromal cells.
The gene expression data indicate a gene regulatory
trend supporting the results from immunohistochemis-
try. In general, pro-angiogenic genes are down-regulated
after both intermittent and daily HBO. However, fewer
genes are significantly changed in the daily HBO treated
group. Figure 3 displays a heatmap of the VEGF-signal-
ling pathway (HSA04370), showing that this important
pro-angiogenic pathway is down-regulated in tumor
cells after intermittent HBO, but not significantly chan-
ged after daily HBO. However, the stromal compartment
does not show the same trend. As we observe an anti-
angiogenic effect in the intermittent group, we might
speculate that the stromal influence is not the most
important contributor to angiogenesis, as the tumor cell
compartment seems to be more influenced by
hyperoxia.
As both HBO groups display tumor growth retarda-
tion, whilst only the intermittent HBO treated group
Figure 3 VEGF pathway, tumor. Heatmap of genes in the VEGF
signaling pathway (HSA04370). The table display gene names,
systematic names, and fold change of gene expression compared
to control of intermittent (I) and daily (D) hyperbaric oxygen (HBO),
respectively. The VEGF pathway is significantly down-regulated by
intermittent HBO treatment of 4T1 mammary tumor cells, but not
by daily treatment. NS = not significant.
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Figure 4 MAPK pathway, tumor (a) and stroma (b). Heatmap of genes in the MAPK pathway (HSA04010). The table display gene names,
systematic names, and fold change of gene expression compared to control of intermittent (I) and daily (D) hyperbaric oxygen (HBO),
respectively. Intermittent and daily HBO treatment suppressed MAPK signaling pathway in both tumor cells and stromal cells compared to
control. NS = not significant.
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influences angiogenesis, we decided to expand the treat-
ment-time of the two groups, in two separate series, to
determine if tumor growth and angiogenesis were chan-
ged after long-term treatments (Additional file 6: Figure
S2). In the extended experiment, one group of animals
was treated with 5 intermittent HBO treatments (Day 1,
4, 7, 10 and 13), whilst the daily group was treated
every day for 13 days. Tumor growth measurements and
CD31 staining of the two long-term HBO treated groups
displayed no significant differences between the two
groups, indicating that other factors must be involved.
Proliferation and apoptosis
Immunohistochemical analysis of proliferation and cell
death showed no significant changes in neither intermit-
tent nor daily HBO when compared to the untreated
control tumors in hot spot areas (Table 1). However,
GSEA showed changes in important cellular pathways
(Additional file 2: Table S1, Additional file 3: TableS2,
Additional file 4: Table S3, Additional file 5: Table S4).
MAPK (HSA04010) is down-regulated in both cellular
compartments after HBO treatments, although not
markedly changed (Figure 4a and 4b). MAPK has been
shown to be important for proliferation, differentiation,
migration and apoptosis [24]. Grb2 is significantly
down-regulated in both tumor and stroma after both
HBO treatments. As GRB2 is an adaptor protein
involved in signal transduction and cell communication,
down-regulation of this gene will impede MAPK-signal
transduction. This might indicate changes in the tumor
after HBO that we were not able to verify with our
immunohistochemical analysis, and that these changes
might support the growth-inhibitory effect.
Invasion and metastasis
Tao et al. [25] studied tumor growth and metastasis in
the 4T1 mammary tumor model using biophotonic ima-
ging. 4T1 cells metastasise to sites affected in human
breast cancer, like lungs, liver, brain and bone [25]. In
the present study, all mice in the supplementary long-
term HBO treatments groups (5 × HBO or 13 × HBO),
20 days after injection, had lung metastases (Additional
file 6: Figure S2). This corresponds to the findings of
Tao et al. [25] where lung metastases were found 15-21
days after injection. However, since we do not have
untreated control tumors at this time point, we can only
speculate on whether or not HBO hinder metastasis.
Haroon et al. [26] found a significant decrease in large
colony lung metastases after HBO treatment, indicating
that HBO restricts the growth of large tumor cell
colonies.
Conclusion
The present in vivo 4T1 mammary tumor model
enabled us to completely separate tumor cells from
stromal cells. The data demonstrated that the two com-
partments are characterized by distinct differences in
gene expressions both in the native state and following
hyperoxic treatment. Furthermore, hyperoxia induced a
significant tumor growth-inhibitory effect, with a signifi-
cant down-regulation of the MAPK pathway. After
intermittent hyperoxic treatment, an anti-angiogenic
effect was observed and reflected in expression trends of
angiogenic genes.
Additional material
Additional file 1: Figure S1 Significantly changed genes in the
tumor and stromal compartment. The number of significantly
expressed genes (FDR < 5%) in tumor cells and stromal cells treated with
daily and intermittent hyperbaric oxygen (HBO), both compared to
control cells. Overlapping genes in the two different compartments are
shown in red.
Additional file 2: Table S1. Cellular processes, pathways and molecular
function. Gene set enrichment analysis (GSEA) after intermittent
hyperbaric oxygen (HBO) treatment of tumor cells.
Additional file 3: Table S2. Cellular processes, pathways and molecular
function. Gene set enrichment analysis (GSEA) after daily hyperbaric
oxygen (HBO) treatment of tumor cells.
Additional file 4: Table S3. Cellular processes, pathways and molecular
function. Gene set enrichment analysis (GSEA) after intermittent
hyperbaric oxygen (HBO) treatment of stroma cells.
Additional file 5: Table S4. Cellular processes, pathways and molecular
function. Gene set enrichment analysis (GSEA) after daily hyperbaric
oxygen (HBO) treatment of stroma cells.
Additional file 6: Figure S2 Tumor growth and metastasis in long-
term HBO treated tumors. 4T1 mammary tumor growth (% of initial
volume) over 14 days in long-term intermittent (n = 7) and long-term
daily (n = 7) hyperbaric oxygen (HBO) treated tumors. Intermittent
treatments were given at day 1, 4 and 7, 10 and 13. Data represent
mean ± SEM. B) Histological section displaying lung metastasis after (B)
long-term intermittent HBO and (C) long-term daily HBO treatment (both
× 100).
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